menu
    • menu
    [{"orgOrder":0,"company":"Biovaxys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BVX-0320","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biovaxys \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biovaxys \/ Inapplicable"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Dinitrophenyl Modified S-spike Protein of SARS-CoV-1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biovaxys \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biovaxys \/ Inapplicable"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Merck Millipore","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BVX-0320","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biovaxys \/ Merck Millipore","highestDevelopmentStatusID":"4","companyTruncated":"Biovaxys \/ Merck Millipore"},{"orgOrder":0,"company":"Biovaxys","sponsor":"The Ohio State University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BVX-0320","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biovaxys \/ The Ohio State University","highestDevelopmentStatusID":"4","companyTruncated":"Biovaxys \/ The Ohio State University"},{"orgOrder":0,"company":"Biovaxys","sponsor":"The Ohio State University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"BVX-0320","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biovaxys \/ The Ohio State University","highestDevelopmentStatusID":"4","companyTruncated":"Biovaxys \/ The Ohio State University"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Bio Elpida","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BVX-0918","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biovaxys \/ Bio Elpida","highestDevelopmentStatusID":"6","companyTruncated":"Biovaxys \/ Bio Elpida"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Deaconess Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"BVX-0918","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biovaxys \/ Deaconess Research Institute","highestDevelopmentStatusID":"6","companyTruncated":"Biovaxys \/ Deaconess Research Institute"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Hospices Civils de Lyon","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"BVX-0918","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biovaxys \/ Hospices Civils de Lyon","highestDevelopmentStatusID":"6","companyTruncated":"Biovaxys \/ Hospices Civils de Lyon"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2024","type":"Private Placement","leadProduct":"BVX-0918","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biovaxys \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biovaxys \/ Undisclosed"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Procare Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BVX-0918C","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biovaxys \/ Procare Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Biovaxys \/ Procare Pharmaceutical"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Sona Nanotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biovaxys \/ Sona Nanotech","highestDevelopmentStatusID":"3","companyTruncated":"Biovaxys \/ Sona Nanotech"}]

    Find Clinical Drug Pipeline Developments & Deals by Biovaxys

    Menu

    Biovaxys

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Biovaxys

                            Canada arrow
                            Pharmex
                            Not Confirmed

                            Biovaxys

                            Canada arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Sona Nanotech

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            BioVaxys & Sona Nanotech Enter Research Collaboration

                            Details : Through the collaboration, BioVaxys will leverage it's DPX Immune Educating Platform in combination with Sona’s Targeted Hyperthermia Therapy to treat solid tumors.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            May 07, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Sona Nanotech

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Biovaxys

                            Canada arrow
                            Pharmex
                            Not Confirmed

                            Biovaxys

                            Canada arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BVX-0918

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : $0.3 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Biovaxys Announces Closing of Third Tranche of Private Placement

                            Details : The company will advance its discovery, preclinical and clinical assets, including BVX-0918 in oncology, antigen desensitization, and other immunological fields based on the DPX technology.

                            Product Name : BVX-0918

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            November 09, 2024

                            Lead Product(s) : BVX-0918

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : $0.3 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Biovaxys

                            Canada arrow
                            Pharmex
                            Not Confirmed

                            Biovaxys

                            Canada arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BVX-1021,BVX-0320

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : The Ohio State University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BioVaxys Sarbecovirus Vaccine Interim Data Excellent Emerging Safety & Tolerability Profile with BVX-1021

                            Details : BVX-1021 is hapten-modified recombinant S1 subunit of the spike protein from the SARS1 virus, whereas BVX-0320, is a hapten-modified recombinant S1 subunit of the spike protein from SARS-CoV-2 ("SARS2"), the virus which causes Covid-19.

                            Product Name : BVX-1021

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            November 16, 2022

                            Lead Product(s) : BVX-1021,BVX-0320

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : The Ohio State University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Biovaxys

                            Canada arrow
                            Pharmex
                            Not Confirmed

                            Biovaxys

                            Canada arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BVX-1021,BVX-0320

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Merck Millipore

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Biovaxys Announces Completed Synthesis of Its Pan-sarbecovirus Vaccine Candidate and Launch of in Vivo Animal ...

                            Details : BVX-1021 using a new batch of recombinant SARS-1 protein from the supplier that screened out the extraneous protein aggregate, has been synthesized using the purified SARS1 protein, OSU is now able to complete the neutralizing antibody studies.

                            Product Name : BVX-1021

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            June 09, 2022

                            Lead Product(s) : BVX-1021,BVX-0320

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Merck Millipore

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Biovaxys

                            Canada arrow
                            Pharmex
                            Not Confirmed

                            Biovaxys

                            Canada arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BVX-0918

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Hospices Civils de Lyon

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters ...

                            Details : BioVaxys expects to be able to prepare its regulatory submission for a EU Phase I study of BVX-0918 in Stage III/Stage IV ovarian cancer near the end of this year, with vaccine supply for the planned clinical study available early May 2022.

                            Product Name : BVX-0918

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            May 18, 2022

                            Lead Product(s) : BVX-0918

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Hospices Civils de Lyon

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Biovaxys

                            Canada arrow
                            Pharmex
                            Not Confirmed

                            Biovaxys

                            Canada arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BVX-0918

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Deaconess Research Institute

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            BioVaxys Enters Critical Tumor Cell Supply Agreement with Deaconess Research Institute for BVX-0918 Bioproduct...

                            Details : Access to ovarian cancer tumor cells is a critical step enabling BioVaxys to validate the manufacturing process for BVX-0918, the Company's autologous haptenized tumor cell vaccine for late-stage ovarian cancer.

                            Product Name : BVX-0918

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            April 25, 2022

                            Lead Product(s) : BVX-0918

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Deaconess Research Institute

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Biovaxys

                            Canada arrow
                            Pharmex
                            Not Confirmed

                            Biovaxys

                            Canada arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BVX-1021,BVX-0320

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : The Ohio State University

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            BioVaxys Announces Bioproduction of BVX-1021 for its Pan-Sarbecovirus Program in Collaboration with The Ohio S...

                            Details : BVX-1021 is the subject of an ongoing research collaboration between The Ohio State University and BioVaxys, announced in December 2021, that is evaluating the Company's novel approach for a "universal vaccine" that can treat a broad range of sarbecoviru...

                            Product Name : BVX-1021

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 17, 2022

                            Lead Product(s) : BVX-1021,BVX-0320

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : The Ohio State University

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Biovaxys

                            Canada arrow
                            Pharmex
                            Not Confirmed

                            Biovaxys

                            Canada arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BVX-0918C

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Procare Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            International Patent Application Filed for Cervical Cancer Vaccine

                            Details : BioVaxys’s cancer vaccine BVX-0918C, created by extracting a patient’s own cancer cells, chemically treating them with a hapten, and re-injecting them into patient to induce an immune response to proteins which are otherwise not immunogenic.

                            Product Name : BVX-0918C

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            February 05, 2022

                            Lead Product(s) : BVX-0918C

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Procare Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Biovaxys

                            Canada arrow
                            Pharmex
                            Not Confirmed

                            Biovaxys

                            Canada arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dinitrophenyl Modified S-spike Protein of SARS-CoV-1

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BioVaxys Files US Patent Application for Pan-Sarbecovirus Vaccine

                            Details : Biovaxys intends to leverage its haptenized viral protein vaccine platform to induce immunity against all or most sarbecoviruses by immunizing people, with a novel vaccine composed of the dinitrophenyl (“DNP”)-modified S-spike protein of SARS-CoV-1.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            October 20, 2021

                            Lead Product(s) : Dinitrophenyl Modified S-spike Protein of SARS-CoV-1

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Biovaxys

                            Canada arrow
                            Pharmex
                            Not Confirmed

                            Biovaxys

                            Canada arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BVX-0918

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Bio Elpida

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BioVaxys and Bioproduction Partner Bio Elpida Begin Construction of GMP Facility to Produce Clinical Supply

                            Details : Bio Elpida is excited and proud to contributing to BioVaxys’ pharmaceutical bioproduction process development of BVX-0918A for the European Phase I clinical.

                            Product Name : BVX-0918

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            January 06, 2021

                            Lead Product(s) : BVX-0918

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Bio Elpida

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth